Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Biofluid Biopsies

Biofluid Biopsies



Keynote Speakers


Ellen Beasley
Senior Vice President, Genomic Health Inc


Xandra Breakefield
Professor, Mass General Hospital (MGH)/Harvard Medical School


Maximilian Diehn
Assistant Professor, Stanford University School of Medicine


Nicholas Dracopoli
Vice President/Head, Johnson & Johnson


Raghu Kalluri
Professor and Chairman, Department of Cancer Biology, University of Texas MD Anderson Cancer Center


Shana Kelley
Professor, University of Toronto


Walter Koch
Vice President, Roche Molecular Systems


Minetta Liu
Associate Professor and Chair, Oncology Research, Mayo Clinic


Ranjan Perera
Associate Professor, Scientific Director Genomics and Bioinformatics, Sanford Burnham Medical Research Institute


Oscar Puig
Biomarker Leader, Hoffmann La Roche


Chamindie Punyadeera
Associate Professor, Institute of Health and Biomedical Innovation, Queensland University of Technology


Dominique PV de Kleijn
Professor Experimental Vascular Surgery, Professor Netherlands Heart Institute, University Medical Center Utrecht, The Netherlands


Frank Slack
Director, Institute for RNA Medicine, Beth Israel Deaconess Medical Center Cancer Center/Harvard Medical School


Hsian-Rong Tseng
Professor, Crump Institute for Molecular Imaging, California NanoSystems Institute, University of California-Los Angeles


David Wong
Felix and Mildred Yip Endowed Chair in Dentistry; Director for UCLA Center for Oral/Head & Neck Oncology Research, University of California-Los Angeles

Overview

The 2nd Annual Biofluid Biopsies and High Value Diagnostics 2015 Conference brings together academic researchers, industry researchers, as well as biotechnology and pharmaceutical companies to explore the expanding and evolving field whereby Circulating Biomarkers of various classes are being evaluated for their potential to be developed into diagnostics for cancer as well as other disease classes.

The Biofluid Biopsies Conference Track focuses primarily on biofluid-based molecular biomarkers, such as circulating tumor DNA (ctDNA) as well as circulating tumor cells (CTCs), and protein-based circulating biomarkers.  There is much interest in the potential of ctDNA for developing biological fluid-based biopsies (such as using plasma, urine, or other biofluids) and the presenters in this track bring together the most up-to-date information and current state-of-the-field.

The High-Value Diagnostics Conference Track explores the potential of various minimally-invasive circulating biomarker classes, such as circulating-free DNA (cfDNA), CTCs, and Extracellular Vesicles (EVs), for development of novel diagnostics for patient monitoring and precision/targeted medicine.

We also explore the front-end sample preparation challenges and approaches for the deployment of various biofluid classes (plasma, serum, urine, cerebrospinal fluid, ovarian follicular fluid, and saliva) into diagnostics development in both the conference tracks.

All conference delegates receive access to both concurrent, co-located conference tracks enabling maximal learning and maximizing networking opportunities.

Present Your Research at this Conference in a Poster to a Worldwide Audience.  Poster Submission Deadline:  November 2, 2015

Agenda Topics

  • Circulating Tumor Cells (CTCs): Potential for Development of Biofluid-based Biopsies
  • Circulating Tumor DNA (ctDNA): Potential for Development of Biofluid-based Biopsies
  • Extracellular Nucleic Acids in the Circulation: Circulating Free DNA, Extracellular RNA -- Value for Developing Biofluid Biopsies
  • Extracellular Vesicles (EVs): Potential for Development of Biofluid-based Biopsies
  • Potential of microRNAs from Biofluids as Biomarkers for Diagnostics Development and as Companion Diagnostics
  • Preparation of Clinical Samples for Biofluid-based Biopsies
  • US vs. EU vs. Asia/Pacific Regulatory Landscape for Novel High-Value Diagnostics

Sponsorship and Exhibition Opportunities

Jeff Fan, Exhibition Manager
jeff@selectbioconferences.com
+1-510-857-4865

Distinguished Faculty

Tony Godfrey, Associate Chair – Research, Department of Surgery, Boston University Medical Center
Chris Karlovich, Associate Director, Molecular Diagnostics, Clovis Oncology, Inc.
Shannon Pendergrast, Chief Scientific Officer, Ymir Genomics
Brian Dougherty, Executive Director, Translational Genomics, Oncology IMED, AstraZeneca R&D
Anton Wellstein, Professor, Georgetown University Medical Center
Sehyun Shin, Professor & Director, Nano-Biofluignostic Engineering Research Center, Korea University and Anam/Guro Hospital of Korea University
Alexander Sasha Vlassov, Senior Manager R&D , Thermo Fisher Scientific
Robert Kinders, Sr. Principal Scientist and Head, Laboratory of Human Toxicology and Pharmacology, Frederick National Laboratory for Cancer Research


Corporate SponsorsWeb SponsorsOffical Journal PartnerNetworking
Drug Discovery WorldU-Networks